MAP3K1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte line, offering a loss-of-function model for the MAP3K1 gene. This product comprises a heterogeneous pool of cells with targeted disruption of MAP3K1, enabling the study of gene function in a physiologically relevant B cell background. The polyclonal format avoids potential artifacts of clonal selection and is well-suited for population-level signaling analyses and high-throughput screening applications.
Raji cells are an Epstein-Barr virus (EBV)-positive B lymphocyte line originally isolated from a patient with Burkitt lymphoma. As a model of mature B lymphocytes, Raji cells mediate humoral immunity through antibody production and antigen presentation, and they retain functional B cell receptor signaling pathways. Their transformed phenotype and established use in immunological and oncological research make them a valuable platform for dissecting signaling networks that govern B cell survival, proliferation, and lymphomagenesis.
MAP3K1 encodes a serine/threonine kinase that integrates signals from upstream receptors such as EGFR, TNFR1, and Toll-like receptors, as well as cytokines like TNF-alpha and EGF. Upon activation, it phosphorylates MKK4 and MKK7, leading to JNK-mediated phosphorylation of c-Jun and regulation of genes controlling apoptosis and survival. MAP3K1 also modulates NF-??B signaling via interactions with TRAF2, RIPK1, TAB1, TAB2, and the IKK complex, affecting p65 activation. Additionally, it can engage the ERK1/2 pathway and crosstalk with p38 MAPK. Key interacting partners include 14-3-3 proteins and JIP1 scaffold proteins, which influence its localization and function.
In the Raji B cell context, MAP3K1 disruption impairs the integration of B cell receptor-derived signals, leading to altered JNK and NF-??B activity and thereby influencing survival and proliferation. This perturbation is directly relevant to the molecular pathology of Burkitt lymphoma and other B cell malignancies, as well as autoimmune and inflammatory diseases. The polyclonal knockout population provides a robust model for dissecting how MAP3K1 coordinates apoptotic and survival signals, and for identifying therapeutic vulnerabilities in lymphomas.
Applications include B cell receptor signaling analyses, MAPK/NF-??B crosstalk studies, apoptosis research, and drug target validation. Typical assays comprise Western blotting for phospho-JNK, phospho-ERK, and phospho-p65; RT-qPCR; RNA-seq; flow cytometry with Annexin V; co-immunoprecipitation; and NF-??B luciferase reporter assays following B cell receptor stimulation. These cells are suitable for functional genomics and immunology research. For more information, please contact Ascent Research.
